Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220679 | 0.77 | HSP90AA1 (0.39) | HSP90AA1P2RX7 | |
| SCHEMBL29579947 | 0.77 | HSP90AA1 (0.39) | HSP90AA1P2RX7GRM4CYP19A1 | |
| SCHEMBL27564370 | 0.77 | HSP90AA1 (0.39) | HSP90AA1P2RX7GRM4CYP19A1 | |
| SCHEMBL14080697 | 0.77 | CA2 (0.47) | HSP90AA1P2RX7 | |
| SCHEMBL1148253 | 0.77 | HSP90AA1 (0.35) | HSP90AA1P2RX7 | |
| Hydrochloric Acid SCHEMBL27772824 | 0.76 | HSP90AA1 (0.38) | HSP90AA1P2RX7GRM4CYP19A1 | |
| Hydrochloric Acid SCHEMBL27855557 | 0.76 | CA2 (0.45) | HSP90AA1P2RX7 | |
| SCHEMBL19422050 | 0.74 | HSP90AA1 (0.37) | HSP90AA1P2RX7 | |
| SCHEMBL19296833 | 0.72 | HSP90AA1 (0.35) | HSP90AA1P2RX7 | |
| SCHEMBL28178793 | 0.71 | HSP90AA1 (0.38) | HSP90AA1P2RX7ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116323623-A | Pyrido [2,3-d ] pyrimidin-4-amines as SOS1 inhibitors | 拜耳公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114269756-A | 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E | 效应疗法股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-107207467-A | 2, 4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | 癌症研究科技有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-102970868-A | Treatment of cancers having K-RAS mutations | CURIS INC | 2013-03-13 | — | — | CN | disclosed |
| CN-102369011-A | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH INC | 2012-03-07 | — | — | CN | disclosed |
| CN-102186857-A | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INT | 2011-09-14 | — | — | CN | disclosed |
| CN-101675053-A | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH INC | 2010-03-17 | — | — | CN | disclosed |
| CN-101511840-A | Phosphoinositide 3-kinase inhibitor compounds and methods of use thereof | GENENTECH INC (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046799-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Genentech, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | HSP90AA1 2179/4885P2RX7 1432/4885ALDH1A1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.